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Objective: Vascular smooth muscle cell (VSMC) proliferation plays an important role in the development of postangio-
plasty or in-stent restenosis, venous graft failure, and atherosclerosis. Our previous work has demonstrated S-phase
kinase-associated protein-2 (Skp2), an F-box subunit of SCFSkp2 ubiquitin ligase, as an importantmediator and common final
pathway for growth factors, extracellular matrices, and cyclic-nucleotides to regulate VSMC proliferation in vitro. However,
whether alteration of Skp2 function also regulates VSMC proliferation in vivo and neointimal thickening postvascular injury
remains unclear. We investigated the effect of Skp2 on VSMC proliferation and neointimal formation in vivo.
Methods and Results: Firstly, we demonstrated that Skp2-null mice developed significantly smaller neointimal areas than
wild-type mice after carotid ligation. Secondly, to further identify a local rather than a systemic effect of Skp2 alteration,
we demonstrated that adenovirus-mediated expression of dominant-negative Skp2 in the balloon-injured rat carotid
artery significantly increased medial p27Kip1 levels, inhibited VSMC proliferation, and the subsequent neointimal
thickening. Lastly, to determine if Skp2 alone is sufficient to drive VSMC proliferation and lesion development in vivo,
we demonstrated that adenovirus-delivery of wild-type Skp2 to the minimally-injured rat carotids is sufficient to
downregulate p27Kip1 protein levels, enhanced medial VSMC proliferation, and the neointimal thickening.
Conclusion: This data provides, we believe for the first time, a more comprehensive understanding of Skp2 in the
regulation of VSMC proliferation and neointimal formation and suggests that Skp2 is a promising target in the treatment
of vasculoproliferative diseases. ( J Vasc Surg 2009;50:1135-42.)
Clinical Relevance:Thismanuscript describes our latest work investigating the role of the Skp2, an F-box protein component
of the SCFskp2 ubiquitin-ligase, in promoting VSMC proliferation, and neointima formation in response to vascular injury in
vivo. Our previous work has identified a major role for Skp2 as a key target for numerous positive and negative growth
regulatory signals in vitro. These signals converge to regulate the expression of Skp2,which then controls cell-cycle progression
bypromotingdegradation of the cyclin-dependent kinase inhibitor, p27Kip1.Until now, there has beennodata in the literature
on the role played by Skp2 in the regulation of VSMC proliferation and neointima formation in vivo. Our current manuscript
describes, we believe for the first time, the important role played by Skp2 in these processes, using both mouse and rat arterial
injury models. This is important because proliferation of VSMCs underlies the development of postangioplasty or post-
stenting restenosis, venous graft failure, and transplant arteriosclerosis. Our work demonstrates for the first time that Skp2 is
a major regulator of VSMC proliferation and neointimal thickening in vivo in response to vascular injury and highlights Skp2
as a potential target for future strategies designed to combat vasculoproliferative diseases.Vascular smooth muscle cell (VSMC) proliferation is
rare in normal adult arteries but increases during athero-
sclerosis. The resulting fibrous cap is vital in protecting the
plaque from rupture and subsequent myocardial infarction.
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the development of postangioplasty or post-stenting reste-
nosis, venous graft failure, and transplant arteriosclerosis.
Tight regulation of VSMC proliferation is therefore essen-
tial. Although a myriad of factors are able to regulate
VSMC proliferation, cell-cycle activation is the final com-
mon pathway,1 and targeting cell-cycle regulation has
emerged as a promising strategy in the treatment of vascu-
loproliferative diseases.
Progression through the G1 phase of the cell-cycle is
regulated by phosphorylation and inactivation of retino-
blastoma (Rb) proteins. This is promoted by the cyclins
(cyclin A, D, and E), which associate with and activate the
cyclin-dependent kinases (CDK2, CDK4, and CDK6).
These CDK:cyclin complexes are subject to negative regula-
tion by the cyclin-dependent kinase inhibitors (CDKIs), such
as the Cip/Kip family of CDKIs (p21Cip1, p27Kip1, and
p57Kip2). Downregulation of CDKIs during late G1 after
addition of growth factors in vitro or balloon injury in
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complexes and subsequent G1/S phase transition.2,3
Skp2 is an F-box component of SCFSkp2 ubiquitin ligase,
implicated in the polyubiquitination and proteasomal
degradation of many cell-cycle regulators,4 including
p27Kip1.5,6 Although many cell-cycle proteins are poten-
tial substrates of Skp2, p27Kip1 is considered most im-
portant,7,8 because it accumulates in Skp2-null cells and
the phenotypic and histologic abnormalities in Skp2-nullmice
are almost completely reversed in Skp2/p27Kip1 doubly-null
mice.8
Increased Skp2 expression along with the related
p27Kip1 deregulation has been deemed a marker of poor
prognosis in cancer disease.9,10 However, the role of Skp2
in vascular disease is less well established. Our previous work
demonstrated that isolated VSMC in culture express high
levels of Skp2. Silencing of Skp2 in these cells with siRNA or
adenovirus-mediated over-expression of dominant-negative
Skp2 (DN-Skp2), increases p27Kip1 levels, and inhibitsVSMC
proliferation, consistent with an essential role for Skp2.11,12
Moreover, both positive (eg, growth factors and matrix con-
tact) and negative (eg, cyclic-nucleotides) factors for VSMC
growth also regulate Skp2 expression in a way reflecting their
effects on VSMC proliferation in vitro.10-12 Despite this,
evidence that Skp2 regulates VSMC proliferation in vivo re-
mains indirect. For example, we showed that elevation of
3=-5=-cyclic adenosine monophosphate (cAMP) in rat carotid
arteries after balloon injury suppresses Skp2 expression, in-
creases p27Kip1 levels, and inhibits both VSMC proliferation
and neointima formation.12 Over-expression of a domi-
nant-negative form of the Rac1 GTPase in the samemodel
showed the same association between decreased Skp2 and
increased p27Kip1 levels with suppression of VSMC prolif-
eration.13 In the present study, we sought for the first time
to provide direct evidence that Skp2 expression regulates
VSMC proliferation in vivo sufficiently to affect the final
neointimal thickening.
MATERIALS
All reagents, except for those stated otherwise, were pur-
chased from Sigma-Aldrich Co (St. Louis, Mo). Antibodies
for Skp2 were obtained fromUS Biological Inc (Swampscott,
Mass) and Invitrogen (Carlsbad, Calif). Mouse anti-p27Kip1
and anti-p21Cip1 antibodies were from BD Transduction
Laboratories (Oxford, United Kingdom). Rabbit anti-
phospho-Rb andmouse anti-bromodeoxyuridine (BrdU) an-
tibodies were bought from Cell Signaling Technology
(Danvers, Mass) and MP Biomedicals (Solon, Ohio), re-
spectively. All secondary antibodies were purchased from
Dako (Burlingame, Calif) and NovaRed from Vector Lab-
oratories (Burlingame, Calif).
METHODS
Animals. Homozygous Skp2/ and wild type con-
trol mice were obtained by crossing heterozygous Skp2/
mice.7 Genotypes of mice were determined by polymerase
change reaction (PCR) of tail tip DNA. Male Sprague-
Dawley (SD) rats were obtained from Charles River (Mar-gate, United Kingdom) or BioLASCO Taiwan Co Ltd
(Taiwan). The housing and care of the animals and all
procedures used adhered to the guidelines and regulations
of the United Kingdom Animal (Scientific Procedures) Act
1986, United Kingdom, and Mackay Memorial Hospital,
Taiwan.
Ligation of mouse common carotid artery. Male
Skp2/ and Skp2/ mice (20-30 grams) were anesthe-
tized by inhalation of isoflurane and oxygen (0.2 L/minute).
The left common carotid artery was ligated near the carotid
bifurcation as described.14 All animals were killed 28 days later
and perfusion fixed with 4% formaldehyde/phosphate buff-
ered saline (PBS) for 7 minutes before excision of ligated
carotid arteries. Vessels were cut into longitudinal sections
to increase the accuracy of neointimal area calculation.
Sections were stained with Elastic Van Gieson (EVG) and
hematoxylin and eosin (H&E) stain and neointimal areas,
defined as the area of tissue within the internal elastic
lamina, quantified using Image Pro analysis software (Me-
diaCybernetics, Bethesda, Md). Vessel diameter (distance
between the external elastic lamellae) and medial thickness
(distance between the internal and external elastic lamellae)
were measured 300-400 m distal to the ligation point.
Balloon injury of rat common carotid artery.
Balloon injury of left common carotid artery was performed
as described by Clowes et al.15 Briefly, male SD rats (400
grams) were anesthetized with an intraperitoneal injection
of a mixture of ketamine hydrochloride (100 mg/kg) and
xylazine (10 mg/kg). The bifurcation of the left common
carotid artery was surgically exposed, and a 2F arterial
embolectomy balloon catheter (Edwards Lifesciences Co,
Irvine, Calif) was introduced through an arteriotomy on
left external carotid artery. The balloon was inflated with
saline and pulled back with rotation through common
carotid artery three times. The injured common carotid
arteries were then subjected to adenovirus-mediated gene
delivery. For cell proliferation assay, animals were injected
subcutaneously with BrdU solution (25 mg/kg) at 17, 9,
and 1 hour before euthanasia.
Filament de-endothelialization of rat common carotid
artery. The procedures of filament de-endothelialization of rat
common carotid artery were modified from the methods
developed by MA Reidy’s group.16,17 Male SD rats were
anesthetized and the left common carotid arteries were
approached as described in balloon injury. The endothe-
lium was then denuded from a carotid artery by a 5-0 nylon
loop. Briefly, the nylon loop was introduced into the left
external carotid artery through a Trocar. The loop was then
slowly pulled back along the common carotid artery with
constant rotation for 30 seconds. The Trocar was re-
trieved and the artery underwent subsequent adenoviral
infection for specific gene expression. Animals were killed
and cell proliferation was evaluated as described in the
previous section.
Adenovirus-mediated gene delivery and expression.
Recombinant replication-defective adenoviruses encoding
wild-type Skp2 (Ad:WT-Skp2), dominant-negative Skp2
(Ad:DN-Skp2), and -galactosidase (Ad:Gal) have been
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with adenoviruses for gene expression, both proximal end
of common carotid artery and internal carotid artery were
temporarily clamped and an aliquot (100 l) of adenovirus
(1  109 pfu/mL)/PBS solution was infused into
the filament- or balloon-injured common carotid artery
through the external carotid artery. Heparin (500 IU/kg)
was given intraperitoneally to prevent arterial thrombosis.
The adenoviral solution was retained in the vessel for 30
minutes and then withdrawn. After ligation of external
carotid artery, the clamps were removed and the blood flow
was restored. The infection rate using this protocol was
40% of medial smooth muscle cells according to the
extent of -galactosidase expression (data not shown).
Immunohistochemical analysis. Rat carotid arteries
were perfused fixed in formalin and cut into0.3-cm-long
pieces (three pieces per artery) before being embedded in
paraffin wax. Each paraffin block containing three pieces of
the same carotid artery was cut into 4-m-thick sections so
that each section had three arterial rings representing arte-
rial lesion 0.3 cm apart in the actual artery. For analysis of
cell proliferation (BrdU) and cell-cycle regulators (hyper-
phosphorylated Rb, p27Kip1, p21Cip1, and Skp2), all cells in
each arterial ring (300-450 cells per ring) were counted
and three arterial rings were analyzed for each carotid
artery. The number of positive cells was expressed as a
percentage of total cell number calculated by counting
hematoxylin counterstained nuclei.
Cell apoptosis was assessed by terminal deoxynucleoti-
dyl transferase biotin-dUTP nick end labeling (TUNEL)
method using DNA Fragmentation Kit (Calbiochem) ac-
cording to the manufacturer’s instruction. Briefly, arterial
sections were incubated with terminal deoxynucleotidyl
transferase (TdT) end-labeling cocktail containing TdT,
Fig 1. Neointimal thickening 28 days after common car
was performed on wild-type or homozygous Skp2-null
groups 28 days post-ligation. Arrows locate ligation pos
was made using Mann-Whitney test.biotin-dUTP, and TdT buffer. The DNase I (0.375 Kunitzunit/l) treated arterial rings were served as positive con-
trol. The arterial rings were then incubated with fluorescein
isothiocyanate (FITC) conjugated avidin. Total cell nuclei
visualized by Hoescht 33258 and nuclei containing cleaved
DNA (FITC-labeled) cells were counted.
For the evaluation of neointimal thickening, arterial
sections were subjected to H&E staining, followed by
neointimal (the tissue within the ring of internal elastic
lamina) and medial areas measured using Image Pro soft-
ware system (MediaCybernetics). The extents of neointi-
mal thickening were presented as intima/media (I/M)
ratios.
Statistical analysis. All data were expressed as mean
SEM. Unpaired two-tailed t test was adopted to test the
significance, if appropriate. Where indicated, data was ana-
lyzed using nonparametric Mann-Whitney test. A P value
less than .05 was considered significant.
RESULTS
To demonstrate the overall effect of Skp2 gene deletion
on the neointimal thickening, Skp2/ and Skp2/mice
were subjected to common carotid arterial ligation, which
induces arterial remodeling, VSMC proliferation, and neo-
intimal thickening.18 Compared with wild-type Skp2 mice
(n  11), Skp2/ mice (n  8) developed significantly
smaller neointimal areas (130,371  29,054 vs 52,903 
35,291 m2; Mann-Whitney test, P  .026) 28 days after
common carotid ligation (Fig 1). However, vessel diameter
(309.5  19.5 m vs 384.8  40.6 m, P  .086 for
wild-type and Skp2-null, respectively) and medial wall
thickness (40.6  2.1 m vs 41.0  2.2 m, P  .9 ) was
not significantly different between wild-type and Skp2-null
mice.
Further mechanistic studies in the mouse model were
ligation in Skp2/ and Skp2/mice. Carotid ligation
. A, Representative longitudinal sections of from both
B, Quantification of neointimal areas. The comparisonotid
mice
ition.impossible because of the small number of longitudinal
ssed a
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ties of breeding additional Skp2-null mice due to low
fertility and fecundity. To more specifically elucidate the
local effect of Skp2 on VSMC proliferation and neointimal
thickening, and to probemore deeply into themechanisms,
we used adenovirus-mediated delivery of either wild-type
Skp2 or DN-Skp2 in balloon- or filament-injured rat ca-
rotid arteries, respectively. DN-Skp2 is an F-box-deleted
Skp2 mutant, which preserves substrate-binding ability but
loses its ability to form SCFSkp2 complex, and, therefore,
inhibits Skp2 function by competing with endogenous
Skp2.5 To test whether local inhibition of Skp2 function
Fig 2. DN-Skp2 up regulates p27Kip1 levels, inhibits VSM
common carotid arteries. Balloon-injured rat common c
Ad:DN-Skp2 by the luminal retention of 100 l adenovira
injected with BrdU (25 mg/kg) at 17, 9, and 1 hour befor
pictures of arterial sections undergoing staining for p27Kip1,
and eosin staining 14 days post injury, as indicated. Scale b
of the immunohistochemistry and I/M ratios. Data are exprealso reduces VSMC proliferation in vivo, DN-Skp2 wasexpressed in balloon-injured rat carotid arteries using an
adenoviral vector. The DN-Skp2 expression significantly
enhanced medial VSMC p27Kip1 expression (from 15.7 
1.3% to 24.1 2.5% of medial VSMC, P .012, n 6 and
5, respectively) but not p21Cip1 expression (from 20.5 
3.2% to 30.2 3.9% of medial VSMC, P .08). DN-Skp2
also inhibited VSMC proliferation measured as BrdU index
(from 37.3  2.5% to 17.0  3.2%, P 	 .01, n  6 and 5,
respectively) and hyper-phosphorylation of Rb protein (from
43.5 4.5% to 25.9 2.8% of medial VSMC, P .012), a
marker of G1-S phase transition, 4 days after injury, com-
pared with vessels infected with a -galactosidase express-
oliferation and neointima formation in balloon-injured rat
arteries were infected with either Ad:Gal (control) or
tion (1 109 pfu/mL) for 30 minutes. The animals were
anasia on the day 4 post balloon-injury.A, Representative
, phospho-Rb, p21Cip1, 4 days post injury andhematoxylin
50 m. Arrows indicate labeled cells. B,Quantified results





arsing control adenovirus (Fig 2). In addition, subsequent
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cantly reduced by DN-Skp2 (I/M ratios, from 1.58 0.20
to 0.49  0.21, P 	 .01, n  5) (Fig 2). Importantly,
frequency of apoptosis, detected by TUNEL staining (Fig
E1, online only), was not increased by expression of dom-
inant-negative Skp2 (less than 0.15% in both Ad: Gal and
Ad:DN-Skp2-infected vessels). This data demonstrates that
Skp2 activity is required for maximal VSMC proliferation
and neointimal lesion development in vivo.
We next sought to determine if increased Skp2 activity
alone, in the absence of a large medial injury inflicted by
balloon angioplasty, can induce VSMC proliferation and
neointimal thickening in vivo. To this end, we used adenoviral-
Fig 3. Skp2 over expression down regulates p27Kip1 lev
common carotid arteries. After filament de-endothelializa
A, Representative pictures of both groups. Carotid arter
staining of Skp2, p27Kip1, phospho-Rb, p21Cip1 and BrdU
were detected in Ad:Gal infected vessels mostly over th
with Ad:Skp2 tended to have Skp2 and BrdU-positive cel
cells.B,Quantification of the immunohistochemistry. Da
P 	 .01, * indicates P 	 .02.delivery of wild-type Skp2 to carotids subjected to fila-ment de-endothelialization. Unlike balloon injury, filament
de-endothelialization results in minor medial injury, mini-
mal VSMC proliferation, and thus, a limited thickness of
neointima.17,19 Compared with filament-injured carotids
infected with control adenovirus (Ad:Gal), those infected
with wild-type Skp2 adenovirus (Ad:WT-Skp2) had sub-
stantially increased Skp2 expression (5  1% compared to
43  5% of medial VSMC, P 	 .01), accompanied by
reduced expression of p27Kip1 (from 18.4 5.4% to 0.6
0.3%, P .016, n 4 and 6, respectively) but not p21Cip1
(from 25.8 4.8 to 18.0 2.4%, P .26).Wild-type Skp2
also enhanced VSMC proliferation measured by BrdU in-
corporation (6  2% to 32  5%, P 	 .01, n  4 and 6,
d increases VSMC proliferation in minimally-injured rat
carotid arteries were infected with Ad:Gal or Ad:Skp2.
ctions were subjected to immunohistochemistry for the
ys post infection. Of note, Skp2- and BrdU-labeled cells
erficial layer of media (arrows), whereas those infected
s-medially. Scale bars 50 m.Arrows indicate labeled






ta arerespectively) and hyper-phosphorylation of Rb (from 9.5
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Eight days after filament injury, Ad:WT-Skp2-infected ca-
rotids gave rise to significantly higher I/M ratios than those
infected with Ad:Gal (0.11  0.03 compared to 0.42 
0.09, P  .024, n  4 and 5, respectively) (Fig 4).
DISCUSSION
Although the role of Skp2 in the oncogenesis is well
recognized,20,21 its role in the regulation of VSMC prolif-
eration is less established. The current studies directly dem-
onstrate for the first time that Skp2 function is involved in
injury-induced VSMC proliferation and neointima devel-
opment in vivo. Furthermore, we demonstrate that Skp2
over-expression is sufficient to drive both proliferation and
lesion development after endothelial denudation in the
absence of major medial injury. These experiments impli-
cate Skp2 as a novel target for the treatment of vasculopro-
liferative diseases, such as vascular restenosis after percuta-
neous vascular intervention.
Numerous factors, such as growth factors, inflamma-
tory mediators, extracellular matrix attachment, cell-cell
contact, and cyclic nucleotides are involved in the regula-
tion of VSMC proliferation.22-24 Nevertheless, the cell-
cycle is the final machinery to integrate and orchestrate
intricate upstream signals to delicately tune VSMC prolif-
eration.1,25 Recent encouraging clinical reports show that
stents coated with rapamycin or paclitaxel, which target
G1-S or G2-M transition, respectively, prevent the occur-
rence of restenosis after coronary intervention.26,27 This
strongly supports the notion that the cell-cycle, the com-
mon final pathway for VSMC proliferation, is an ideal
target for the treatment of vascular restenosis and, by
Fig 4. Wild-type Skp2 enhances neointimal thickening
treated as in Fig 4. Eight days after filament de-endoth
subjected to hematoxylin and eosin staining as describe
bar  100 m. B, Quantified results of I/M ratios.implication, other vasculoproliferative diseases.Our previous studies established Skp2 as an important
mediator in the final common pathway for VSMC prolifer-
ation in vitro.10 For example, we showed that positive
mediators for VSMC proliferation (growth factors and
matrix contact) increase Skp2 levels, whereas negative reg-
ulators (cyclic nucleotides) decrease them.11,12 These ef-
fects are mediated through regulation of focal adhesion
kinase,11,12 phosphoinositide 3-kinase,28 and Rac1
13 sig-
naling pathways. DN-Skp2 blocks the stimulation of
VSMC proliferation after growth factor addition, whereas
overexpression of native Skp2 reverses the inhibitory effects
of cyclic-nucleotides.12
In vivo we also demonstrated that Skp2 expression
levels are strikingly enhanced after balloon injury with a
time course that perfectly mirrors that of VSMC prolifera-
tion.12 Moreover, adventitial application of forskolin (an
activator of endogenous cyclic AMP levels) inhibited Skp2
expression, VSMC proliferation, and neointima formation.
This indirect evidence supports the role of Skp2 in VSMC
proliferation in vivo. Justified by this correlative evidence,
we directly tested for the first time whether Skp2 is neces-
sary and sufficient for VSMC proliferation and neointima
formation in vivo after vascular injury in mice and rats.
Initially, we demonstrated that neointima formation after
carotid ligation was significantly attenuated in Skp2/
mice, compared with that in Skp2/ mice. Although
Skp2/ mice tend to be smaller than their wild-type
counterparts7 we found that carotid diameter and medial
thickness was not different and no gross vessel abnormali-
ties were observed at the time of surgery. Impaired lesion
formation in these mice is consistent with previous reports
of reduced rates of cellular proliferation.7 It is important to
nimally-injured rat carotid arteries. Carotid arteries were
zation, the carotids from both treatment groups were
ig 2. A, Representative pictures of both groups. Scalein mi
eliali
d in Fnote that impaired lesion formation in Skp2/mice could
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bone marrow progenitor cells, inflammatory cells, fibro-
blasts, and endothelial cells, all of which may interact with
VSMC and contribute significantly to the final neointimal
thickening.29-31 To more specifically pinpoint the effects of
Skp2 inhibition on local VSMC and neointimal thickening,
DN-Skp2 was expressed in balloon-injured rat carotid ar-
teries via adenovirus-mediated gene transfer. The expres-
sion of DN-Skp2 resulted in elevated levels of the CDKI
p27Kip1, which is normally rapidly downregulated soon
after vascular injury.32,33 These observations are consistent
with the hypothesis that injury-induced expression of Skp2
is responsible for the downregulation of p27Kip1 after vas-
cular injury. Downregulation of p27Kip1 is thought to be an
important step in removing the brake on proliferation,
because forced expression of p27Kip1 inhibits S-phase entry
and neointima formation after balloon injury34 and
p27Kip1-null mice display a hyper-proliferative phenotype
and exaggerated responses to vascular injury. We showed
here that expression of DN-Skp2 prevented downregula-
tion of p27Kip1 and resulted in significantly reduced levels
of hyperphosphorylated Rb protein, a marker of G1-S
transition, reduced rates of VSMC proliferation and smaller
neointimal lesions. Expression of DN-Skp2 did not, how-
ever, significantly effect the expression of p21Cip1, even
though our previous data demonstrated that Skp2 regulates
p21Cip1 levels in VSMC in vitro.28 However, p21Cip1 reg-
ulation seems to be more complicated than that of p27Kip1
in these cells. The p21Cip1 levels actually increase in re-
sponse to mitogen stimulation, coordinately with increases
in Skp2, which functions to maintain p21Cip1 within
growth permissive levels.28 This complex pattern of regu-
lation may account for the lack of a significant change in
p21Cip1 in this study. Importantly, apoptosis rates were not
increased in vessels expressing DN-Skp2, indicating that
reduced lesion formation was due to inhibition of prolifer-
ation rather than increased cell death. Likewise, expression
of DN-Skp2 in VSMC in vitro does not result in increased
rate of apoptosis (unpublished data). Taken together with
our observations from Skp2/ mice, our data demon-
strates that injury-induced expression of Skp2 is a major
mechanism regulating p27Kip1 levels and is essential for
VSMC proliferation and the final neointimal thickening.
We previously demonstrated that exogenous expres-
sion of Skp2 is able to force VSMC to enter S-phase in the
uninjured rat aorta in organ cultures.11 In the present
study, we asked whether increased Skp2 expression would
be sufficient to induce VSMC proliferation and neointimal
lesion development, in the absence of major medial injury
in vivo. Consistent with previous reports,16 we showed that
filament de-endothelialization of rat carotid artery caused
minimal levels of VSMC proliferation and neointimal thick-
ening, and only a small increase in Skp2 expression. How-
ever, forced expression of wild-type Skp2 resulted in a
remarkable reduction of p27Kip1 expression and a transme-
dial increase of BrdU-labeled cells. This demonstrates that
Skp2 alone is sufficient to promote p27Kip1 downregula-tion and VSMC proliferation in the absence of major
medial injury.
Taken together, our data provides the first direct and
robust evidence that Skp2 plays an important role in pro-
moting VSMC proliferation and neointimal thickening in
vivo in response to vascular injury. These results suggest
that Skp2 may represent an attractive target for future gene
or pharmacologic-based therapies to combat vasculoprolif-
erative diseases. Targeting Skp2 in this way may be more
effective than approaches designed to block the activity of
single downstream cell-cycle regulators, such as p27Kip1,
because Skp2 regulates the levels and activity of multiple
cell-cycle proteins. However, more work is required to
elucidate the role and regulation of Skp2 in other vascular
cells, particularly endothelial cells, before this may become
a reality.
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